Merck Cancer Drug Wins US Priority Review
Merck received US priority review for its experimental endometrial cancer drug after a late-stage trial showed it significantly extended patient survival. The treatment reduced the risk of death by 32 percent compared to standard chemotherapy.
Xurve View
Insights:
Xurve View
MERCK & CO. INC. secured priority review from the United States health regulator for its targeted cancer drug, extending survival in advanced endometrial cancer trials. The experimental therapy reduced the risk of death by 32% compared to standard chemotherapy in late-stage trials. Jefferies analysts project peak sales of $900 million in endometrial cancer and $9 billion across all potential indications.
